Successful cardiac ablation for AF
Documented freedom from AF recurrence (symptomatic or asymptomatic arrhythmic recurrences lasting longer than 30 seconds) 3 months after successful cardiac ablation (AF recurrence during 3-month blanking period is excluded).
Patient must have been on a commercially approved anticoagulation therapy for at least two (2) months prior to randomization in the OAT Study.
CHADS2 score = 2 or CHA2DS2-VASc score (=3)
Left ventricular ejection fraction > 25%
LA size < 65
High risk for thromboembolic events (i.e., CHADS2 score = 2 or CHA2DS2-VASc score = 3) and require OAT before undergoing cardiac ablation
Able and willing to comply with all pre- and follow-up testing and requirements
Signed informed consent form
Age 18 years or older
